Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

AIDS

Volumn 17, Issue 6, 2003, Pages 831-840

  Arnaiz, Juan A ^a   Mallolas, Josep ^a   Podzamczer, Daniel ^b   Gerstoft, Jan ^c   Lundgren, Jens D ^d   Cahn, Pedro ^e   Fätkenheuer, Gerd ^f   D'Arminio Monforte, Antonella ^g   Casiró, Arnaldo ^h   Reiss, Peter ⁱ   Burger, David M ^j   Stek, Michael ^k   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c Rigshospitalet   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

^e FUNDACIÓN HUÉSPED   (Argentina)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY OF MILAN   (Italy)

^h Hospital General De Agudos Teodoro Alvarez   (Argentina)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Antiretroviral therapy; Clinical trials; Combination therapy; Protease inhibitors

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSURIA; FEMALE; FLANK PAIN; HAIR LOSS; HEADACHE; HEMATURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INGROWN NAIL; LABORATORY TEST; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0013309175     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304110-00008     Document Type: Article

References (26)

1. Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999, 58:1165-1203.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
3. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
5. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Ther 1998, 3:215-220.
6. Ruane P, Mendonça J, Timerman A, Cernohous P, Bauer E, Bernstein B, et al. Kaletra vs. nelfinavir in antiretroviral-naive subjects: week 60 comparison in a phase III, blinded, randomized clinical trial. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 6].
7. Becker S, Brun S, Bertz R, Xu Y, Clumeck N, Lazzarin A, et al. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24 week safety/efficacy evaluation in multiple PI experienced patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [abstract 697].
8. Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998, 42:2784-2791.
9. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, Mulder JW, Schreij G, Hsu A, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999, 13:F95-F99.
10. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol 2000, 40:649-674.
11. Hugen PW, Burger DM, ter Hofstede HJ, Koopmans PP, Stek M, Hekster YA, et al. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr 2000, 25:236-245.
12. van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000, 14:1187-1194.
13. Mallolas J, Blanco JL, Sarasa M, Giner V, Martinez E, Garcia-Viejo MA, et al. Dose finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients. J Acquir Immune Defic Syndr 2000, 25:229-235.
14. Burger DM, Hugen PW, Aarnoutse RE, Dieleman JP Prins JM, van der Poll T, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001, 26:218-224.
15. Casagrande JT, Pike MD, Smith PG. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978, 34:483-486.
16. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports 1978, 62:1037-1040.
17. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fatkenheuer G, et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS 2000, 14:1181-1185.
18. Barreiro P, Soriano V, Oiler V, Gonzalez-Lahoz J. Potent activity but limited tolerance of ritonavir plus indinavir in salvage interventions. J Acquir Immune Defic Syndr 2000, 24:488.
19. Aarnoutse R, Wasmuth J, Fätkenheuer G, Schneider K, Reiss P, Burger D, et al. Indinavir/ritonavir 800/100mg twice daily (BID) should be taken with food to prevent toxic indinavir peak plasma levels. XIV International Conference on AIDS. Barcelona, July 2002 [abstract TuPeB4570].
20. Boyd M, Duncombe C, Newell M, Ungseghapand C, Rugsrungtham K, Khongphattanayothin M, et al. HIV-NAT 005: indinavir/ritonavir vs indinavir in combination with AZT/3TC for the treatment of HIV infection in nucleoside experienced patients: a randomised, open label trial. Presented at the Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
21. Fischl M, Young B, Watkins M, Arduino R, Jensen E, Wilson H, et al. Direct study: a multicenter, open-label, 24-wk pilot study with a 24-wk extension to evaluate the safety, tolerability and efficacy of indinavir (IDV)-ritonavir (RTV) 800/100 bid in combination with D4T plus 3TC in HIV-infected individuals (Merck Protocol 094). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 2001 [abstract I-1923].
22. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999, 13:473-478.
23. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000, 20:2625-2629.
24. Smith JH, Martin GJ, Decker CF Hyperlipidemia associated with the use of protease inhibitors. Clin Infect Dis 2000, 31:207-208.
25. Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusteda L, Fortuna P, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquit Immune Defic Syndr 2000, 23:236-245.
26. Katlama C, Lamotte C, Hair Mohand H, Calvez V, Agher R, Bricaire F, et al. Ritonavir (RTV)/indinavir (IDV) (100/400 mg bid): A simple, effective and well tolerated PI containing regimen. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 214].